» Articles » PMID: 37593069

Intradural Intramedullary Spinal Cord Glioblastoma: A Case Report

Overview
Journal Cureus
Date 2023 Aug 18
PMID 37593069
Authors
Affiliations
Soon will be listed here.
Abstract

Primary spinal cord glioblastoma multiforme (GBM) remains uncommon and typically affects males and patients during their fifth decade of life. Our case demonstrates a 77-year-old woman who initially presented with right arm paresthesia and limited range of motion and was subsequently diagnosed with primary spinal cord GBM. Our case illustrates an atypical and nonspecific neurological presentation highlighting that spinal cord GBM can have a more indolent course, unlike what current literature suggests. It also emphasizes the importance of considering a multimodal approach when managing atypical neurological symptoms and considering an early intervention, including magnetic resonance imaging, to rule out occult neoplasm in an appropriate clinical setting, thus preventing delay in the diagnosis. This case further emphasizes the role of molecular biomarkers of tumors, including isocitrate dehydrogenase mutation as well as methylguanine-DNA methyltransferase promoter methylation status, that can independently guide and affect the treatment outcomes in this patient population.

Citing Articles

A rare case of atypical intradural extramedullary glioblastoma diagnosed utilizing next-generation sequencing and methylation profiling: illustrative case.

Shelton W, Mathews A, Aljiboori K, Nix J, Gokden M, Rodriguez A J Neurosurg Case Lessons. 2024; 7(16).

PMID: 38621302 PMC: 11023011. DOI: 10.3171/CASE24103.

References
1.
Gao W, Wang X, Li F, Shi W, Li H, Zeng Q . Cho/Cr ratio at MR spectroscopy as a biomarker for cellular proliferation activity and prognosis in glioma: correlation with the expression of minichromosome maintenance protein 2. Acta Radiol. 2018; 60(1):106-112. DOI: 10.1177/0284185118770899. View

2.
Nam Y, Koo H, Yang Y, Shin S, Zhu Z, Kim D . Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. Genome Med. 2023; 15(1):16. PMC: 10010007. DOI: 10.1186/s13073-023-01165-8. View

3.
Olar A, Aldape K . Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2013; 232(2):165-77. PMC: 4138801. DOI: 10.1002/path.4282. View

4.
Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

5.
Ginat D, Schaefer P . Imaging guidelines and findings of extracranial glioblastoma. J Neurooncol. 2014; 118(1):9-18. DOI: 10.1007/s11060-014-1404-7. View